|
AR058135A1
(es)
|
2005-10-21 |
2008-01-23 |
Chugai Pharmaceutical Co Ltd |
Agentes para el tratamiento de cardiopatias
|
|
CA2648644C
(en)
|
2006-04-07 |
2016-01-05 |
Osaka University |
Muscle regeneration promoter
|
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
|
ME00519B
(me)
|
2006-06-02 |
2011-10-10 |
Regeneron Pharma |
Antitijela visokog afiniteta prema humanom il-6 receptoru
|
|
US8629244B2
(en)
|
2006-08-18 |
2014-01-14 |
Ablynx N.V. |
Interleukin-6 receptor binding polypeptides
|
|
WO2008071685A1
(en)
*
|
2006-12-13 |
2008-06-19 |
Ablynx N.V. |
Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex
|
|
WO2012130874A1
(en)
|
2011-03-28 |
2012-10-04 |
Ablynx Nv |
Bispecific anti-cxcr7 immunoglobulin single variable domains
|
|
US9512236B2
(en)
|
2006-12-19 |
2016-12-06 |
Ablynx N.V. |
Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
|
US9725514B2
(en)
|
2007-01-23 |
2017-08-08 |
Shinshu University |
Chronic rejection inhibitor
|
|
EP2158315B1
(en)
|
2007-06-25 |
2016-03-23 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Methods of modifying antibodies, and modified antibodies with improved functional properties
|
|
WO2009010539A2
(en)
*
|
2007-07-19 |
2009-01-22 |
Ablynx. N.V. |
Receptor for interleukin-6 (il-6) from macaca fascicularis
|
|
WO2009095489A2
(en)
*
|
2008-02-01 |
2009-08-06 |
Ablynx N.V. |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
|
|
EP2247616A2
(en)
*
|
2008-03-05 |
2010-11-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making and uses thereof
|
|
EP2268668A1
(en)
|
2008-04-17 |
2011-01-05 |
Ablynx N.V. |
Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
|
|
US10717781B2
(en)
|
2008-06-05 |
2020-07-21 |
National Cancer Center |
Neuroinvasion inhibitor
|
|
CN102112155B
(zh)
|
2008-06-05 |
2016-08-10 |
埃博灵克斯股份有限公司 |
针对病毒包膜蛋白的氨基酸序列和用于治疗病毒疾病的包含其的多肽
|
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
|
AU2009273251B2
(en)
|
2008-07-22 |
2014-12-18 |
Ablynx Nv |
Amino acid sequences directed against multitarget scavenger receptors and polypeptides
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
WO2010043057A1
(en)
|
2008-10-14 |
2010-04-22 |
National Research Counsil Of Canada |
Bsa-specific antibodies
|
|
JP5823871B2
(ja)
*
|
2008-12-10 |
2015-11-25 |
アブリンクス エン．ヴェー． |
血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン／Ｔｉｅシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド
|
|
EP2370465B1
(en)
|
2008-12-19 |
2019-01-23 |
Ablynx N.V. |
Genetic immunization for producing immunoglobulins against cell-associated antigens such as p2x7, cxcr7 or cxcr4
|
|
CA2746964C
(en)
|
2009-01-14 |
2018-07-24 |
Marie-Paule Lucienne Armanda Bouche |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
BRPI1007371A2
(pt)
*
|
2009-01-29 |
2018-03-27 |
Abbott Lab |
proteínas de ligação a il-1
|
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
RU2524152C2
(ru)
*
|
2009-03-19 |
2014-07-27 |
Чугаи Сейяку Кабусики Кайся |
Средство для лечения ревматоидного артрита
|
|
WO2010115995A2
(en)
*
|
2009-04-10 |
2010-10-14 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
|
WO2010115998A2
(en)
*
|
2009-04-10 |
2010-10-14 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
|
US9464138B2
(en)
|
2009-04-30 |
2016-10-11 |
Ablynx N.V. |
Method for the production of domain antibodies
|
|
NZ597314A
(en)
|
2009-06-05 |
2013-07-26 |
Ablynx Nv |
Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
|
|
DK2451839T3
(da)
|
2009-07-10 |
2020-07-13 |
Ablynx Nv |
Fremgangsmåde til produktion af variable domæner
|
|
WO2011026945A1
(en)
|
2009-09-03 |
2011-03-10 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
US20120283415A1
(en)
*
|
2009-09-10 |
2012-11-08 |
Ucb Pharma S.A. |
Multivalent Antibodies
|
|
UY32917A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moléculas de unión a dll-4
|
|
UY32920A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moleculas de unión biespecíficas para la terapia anti-angiogénesis
|
|
WO2011042398A1
(en)
|
2009-10-09 |
2011-04-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
|
|
US9644022B2
(en)
|
2009-11-30 |
2017-05-09 |
Ablynx N.V. |
Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
WO2011067160A1
(en)
|
2009-12-01 |
2011-06-09 |
Ablynx Nv |
Von willebrand factor specific binding agents and uses thereof
|
|
FI3309176T3
(fi)
|
2009-12-14 |
2026-01-09 |
Ablynx Nv |
Immunoglobuliinin yksittäinen vaihteleva domeeni -vasta-aineita ox40l:ää vastaan, konstrukteja ja niiden terapeuttinen käyttö
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
|
CA2788993A1
(en)
|
2010-02-05 |
2011-08-11 |
Ablynx N.V. |
Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
|
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
|
JP5951508B2
(ja)
|
2010-02-11 |
2016-07-13 |
アブリンクス エン．ヴェー． |
エアロゾルの調製のための方法及び組成物
|
|
US20130012916A1
(en)
|
2010-02-11 |
2013-01-10 |
Glide Pharmaceutical Technologies Limited |
Delivery of immunoglobulin variable domains and constructs thereof
|
|
CN102781962B
(zh)
|
2010-03-03 |
2014-12-10 |
阿布林克斯公司 |
双互补位A-β结合多肽
|
|
WO2011117423A1
(en)
|
2010-03-26 |
2011-09-29 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against cxcr7
|
|
US9101674B2
(en)
|
2010-03-29 |
2015-08-11 |
Vib Vzw |
Targeting and in vivo imaging of tumor-associated macrophages
|
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
WO2013174537A1
(en)
|
2012-05-24 |
2013-11-28 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
NZ603570A
(en)
|
2010-05-20 |
2014-12-24 |
Ablynx Nv |
Biological materials related to her3
|
|
US9539322B2
(en)
|
2010-05-28 |
2017-01-10 |
National University Corporation Hokkaido University |
Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
|
|
AU2011267036B2
(en)
*
|
2010-06-17 |
2015-01-29 |
Universiteit Gent |
Increased protein expression through increased membrane formation
|
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
|
US20120225081A1
(en)
|
2010-09-03 |
2012-09-06 |
Boehringer Ingelheim International Gmbh |
Vegf-binding molecules
|
|
US11644471B2
(en)
|
2010-09-30 |
2023-05-09 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
|
EP2621953B1
(en)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biological materials related to c-met
|
|
KR101832040B1
(ko)
|
2010-11-08 |
2018-04-04 |
노파르티스 아게 |
Ｃｘｃｒ２ 결합 폴리펩티드
|
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
|
US20130078247A1
(en)
|
2011-04-01 |
2013-03-28 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to dii4 and ang2
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
US9534039B2
(en)
|
2011-05-09 |
2017-01-03 |
Ablynx N.V. |
Method for the production of immunoglobulin single variable domains
|
|
AU2012264809B2
(en)
|
2011-05-27 |
2017-05-04 |
Ablynx Nv |
Inhibition of bone resorption with RANKL binding peptides
|
|
HRP20180443T1
(hr)
|
2011-06-21 |
2018-04-20 |
Vib Vzw |
Povezujuće domene usmjerene protiv gpcr-a: g proteinski kompleksi i njihove derivirane uporabe
|
|
EP4350345A3
(en)
|
2011-06-23 |
2024-07-24 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
|
|
CA3141978A1
(en)
|
2011-06-23 |
2012-12-27 |
Ablynx Nv |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
|
WO2012175740A1
(en)
|
2011-06-23 |
2012-12-27 |
Ablynx Nv |
Immunoglobulin single variable domains directed against ige
|
|
EP2944654A1
(en)
|
2011-06-23 |
2015-11-18 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
|
|
EP2723771B1
(en)
|
2011-06-23 |
2019-09-11 |
Ablynx NV |
Serum albumin binding proteins
|
|
WO2013024059A2
(en)
|
2011-08-17 |
2013-02-21 |
Glaxo Group Limited |
Modified proteins and peptides
|
|
US10138302B2
(en)
|
2011-09-23 |
2018-11-27 |
Ablynx N.V. |
Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
|
|
JP6219287B2
(ja)
|
2011-09-30 |
2017-10-25 |
アブリンクス エン．ヴェー． |
ｃ−Ｍｅｔに関連する生物学的物質
|
|
US9346884B2
(en)
|
2011-09-30 |
2016-05-24 |
Ablynx N.V. |
Biological materials related to c-Met
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
EP2807266B1
(en)
|
2012-01-26 |
2020-01-15 |
Amgen Inc. |
Growth differentiation factor 15 (gdf-15) polypeptides
|
|
AP2014007791A0
(en)
|
2012-02-27 |
2014-07-31 |
Boehringer Ingelheim Int |
CX3CR1-binding polypeptides
|
|
DK2831111T3
(en)
|
2012-03-30 |
2019-04-29 |
Boehringer Ingelheim Int |
Ang2-binding molecules
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
|
PT2951201T
(pt)
|
2013-01-30 |
2018-01-09 |
Univ Brussel Vrije |
Novos polipéptidos quiméricos para rastreamento e fins de descoberta de fármacos
|
|
PL2953973T3
(pl)
|
2013-02-05 |
2020-01-31 |
Vib Vzw |
Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania
|
|
EP2968487B1
(en)
|
2013-03-15 |
2019-01-30 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
|
|
JP6442404B2
(ja)
|
2013-06-11 |
2018-12-19 |
国立研究開発法人国立精神・神経医療研究センター |
再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
|
|
DK3027642T3
(da)
|
2013-07-31 |
2020-11-02 |
Amgen Inc |
Vækstdifferentieringsfaktor 15 (gdf-15)-konstruktioner
|
|
EP3447068A1
(en)
|
2013-11-04 |
2019-02-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Synthetic single domain antibody
|
|
EP2873680A1
(en)
*
|
2013-11-13 |
2015-05-20 |
F.Hoffmann-La Roche Ag |
Oligopeptide and methods for producing conjugates thereof
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
WO2015097289A1
(en)
|
2013-12-24 |
2015-07-02 |
Vib Vzw |
Secretion and functional display of chimeric polypeptides
|
|
EP3099707B1
(en)
|
2014-01-30 |
2021-12-29 |
Vib Vzw |
Opioid receptor binding agents and uses thereof
|
|
EP3143403B1
(en)
|
2014-05-16 |
2021-10-27 |
Ablynx N.V. |
Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
|
|
EP3693386A1
(en)
|
2014-05-16 |
2020-08-12 |
Ablynx NV |
Immunoglobulin variable domains
|
|
KR20250099289A
(ko)
|
2014-05-16 |
2025-07-01 |
아블린쓰 엔.브이. |
개선된 면역글로불린 가변 도메인
|
|
NL2013007B1
(en)
|
2014-06-16 |
2016-07-05 |
Ablynx Nv |
Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
CA2955554C
(en)
|
2014-07-22 |
2022-07-05 |
Vib Vzw |
Methods to select for agents that stabilize protein complexes
|
|
EP3954373A1
(en)
|
2014-10-07 |
2022-02-16 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
EP3209327A1
(en)
|
2014-10-21 |
2017-08-30 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
|
AU2015366284B2
(en)
|
2014-12-19 |
2021-07-22 |
Ablynx N.V. |
Cysteine linked nanobody dimers
|
|
TWI873632B
(zh)
|
2015-02-27 |
2025-02-21 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
|
WO2016150845A1
(en)
*
|
2015-03-20 |
2016-09-29 |
Ablynx Nv |
Glycosylated immunoglobulin single variable domains
|
|
WO2016156466A1
(en)
|
2015-03-31 |
2016-10-06 |
Vhsquared Limited |
Peptide construct having a protease-cleavable linker
|
|
IL254591B
(en)
|
2015-03-31 |
2022-07-01 |
Vhsquared Ltd |
Polypeptides
|
|
AU2016239844B2
(en)
|
2015-04-02 |
2021-05-13 |
Ablynx N.V. |
Bispecific CXCR4-CD-4 polypeptides with potent anti-HIV activity
|
|
EP3286224A4
(en)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
CN114920847A
(zh)
|
2015-05-13 |
2022-08-19 |
埃博灵克斯股份有限公司 |
基于cd3反应性的t细胞募集多肽
|
|
PT3294768T
(pt)
|
2015-05-13 |
2019-11-05 |
Ablynx Nv |
Polipétidos de recrutamento de células t com base na reatividade do tcr alfa/beta
|
|
EP3299810B1
(en)
|
2015-05-19 |
2021-07-07 |
National Center of Neurology and Psychiatry |
Method for determining application of novel therapy to multiple sclerosis (ms) patient
|
|
MX383614B
(es)
|
2015-05-21 |
2025-03-14 |
Harpoon Therapeutics Inc |
Proteinas de union triespecificas y metodos de uso.
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
NO2768984T3
(show.php)
|
2015-11-12 |
2018-06-09 |
|
|
|
CN108290943A
(zh)
|
2015-11-13 |
2018-07-17 |
埃博灵克斯股份有限公司 |
改进的血清白蛋白结合免疫球蛋白可变结构域
|
|
EA201891165A1
(ru)
|
2015-11-18 |
2018-11-30 |
Мерк Шарп И Доум Корп. |
Молекулы, связывающие pd1 и/или lag3
|
|
MA43258A
(fr)
|
2015-11-18 |
2018-09-26 |
Merck Sharp & Dohme |
Liants pd1/ctla4
|
|
US10501542B2
(en)
|
2015-11-18 |
2019-12-10 |
Merck Sharp & Dohme Corp. |
CTLA4 binders
|
|
AU2016357460B2
(en)
|
2015-11-18 |
2023-07-27 |
Ablynx Nv |
Improved serum albumin binders
|
|
MX2018006377A
(es)
|
2015-11-27 |
2018-09-05 |
Ablynx Nv |
Polipeptidos que inhiben cd40l.
|
|
KR102802241B1
(ko)
|
2015-12-04 |
2025-05-07 |
베링거 인겔하임 인터내셔날 게엠베하 |
종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
|
|
WO2017125578A1
(en)
|
2016-01-21 |
2017-07-27 |
Vhsquared Limited |
Polypeptides
|
|
CA3017813C
(en)
|
2016-03-17 |
2021-12-07 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
CA3022697A1
(en)
|
2016-05-02 |
2017-11-09 |
Ablynx Nv |
Treatment of rsv infection
|
|
WO2017201488A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
PT3461261T
(pt)
|
2016-05-20 |
2025-07-31 |
Harpoon Therapeutics Inc |
Proteínas de ligação ao cd3 de fragmento variável de cadeia única
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
EP3471761A2
(en)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
|
EP3475699B1
(en)
|
2016-06-23 |
2022-07-06 |
Ablynx N.V. |
Improved pharmacokinetic assays for immunoglobulin single variable domains
|
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
|
US11098113B2
(en)
|
2016-09-15 |
2021-08-24 |
Vib Vzw |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
|
AU2017332721B2
(en)
|
2016-09-20 |
2023-11-09 |
Sara BUHRLAGE |
Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
|
|
WO2018060453A1
(en)
|
2016-09-30 |
2018-04-05 |
Vhsquared Limited |
Compositions
|
|
JP7222888B2
(ja)
|
2016-11-16 |
2023-02-15 |
アブリンクス エン．ヴェー． |
Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド
|
|
JP6812551B2
(ja)
|
2016-11-23 |
2021-01-13 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原結合タンパク質
|
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
|
|
JP7626577B2
(ja)
|
2016-11-28 |
2025-02-07 |
中外製薬株式会社 |
リガンド結合活性が調整可能なリガンド結合分子
|
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
|
IL266907B2
(en)
|
2016-12-07 |
2024-07-01 |
Ablynx Nv |
Immunoglobulin sites with a single variable enhance serum albumin binding
|
|
WO2018111099A1
(en)
|
2016-12-12 |
2018-06-21 |
Stichting Vumc |
Biomarkers and treatments for cerebral amyloid angiopathy (caa)
|
|
KR102653724B1
(ko)
|
2017-01-17 |
2024-04-02 |
아블린쓰 엔.브이. |
개선된 혈청 알부민 결합제
|
|
SG10202108972RA
(en)
|
2017-01-17 |
2021-09-29 |
Ablynx Nv |
Improved serum albumin binders
|
|
EP3589725A1
(en)
|
2017-02-28 |
2020-01-08 |
Vib Vzw |
Means and methods for oral protein delivery
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
CN110546506B
(zh)
|
2017-03-31 |
2023-04-04 |
埃博灵克斯股份有限公司 |
改进的免疫原性测定法
|
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
|
|
EP3621990A1
(en)
|
2017-05-11 |
2020-03-18 |
VIB vzw |
Glycosylation of variable immunoglobulin domains
|
|
CN110891974B
(zh)
|
2017-05-12 |
2021-08-06 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
|
KR20200026810A
(ko)
|
2017-05-12 |
2020-03-11 |
하푼 테라퓨틱스, 인크. |
Msln 표적화 삼중 특이적 단백질 및 사용 방법
|
|
JP7216024B2
(ja)
|
2017-05-31 |
2023-01-31 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
腫瘍細胞におけるＷｎｔシグナル伝達と拮抗するポリペプチド
|
|
TW202417517A
(zh)
|
2017-06-02 |
2024-05-01 |
德商麥克專利有限公司 |
與ｍｍｐ１３結合之免疫球蛋白
|
|
CA3065630A1
(en)
|
2017-06-02 |
2018-12-06 |
Ablynx Nv |
Aggrecan binding immunoglobulins
|
|
RS66191B1
(sr)
|
2017-06-02 |
2024-12-31 |
Merck Patent Gmbh |
Imunoglobulini koji vezuju adamts
|
|
CN110997717A
(zh)
|
2017-06-02 |
2020-04-10 |
默克专利股份有限公司 |
结合adamts5、mmp13和聚蛋白聚糖的多肽
|
|
EP3634496A4
(en)
|
2017-06-06 |
2021-09-08 |
Dana-Farber Cancer Institute, Inc. |
METHODS FOR SENSITIZING CANCER CELLS TO T-LYMPHOCYTES-MEDIA DESTRUCTION BY MODULATION OF MOLECULAR PATHWAYS
|
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
|
CA3070253A1
(en)
|
2017-07-19 |
2019-01-24 |
Vib Vzw |
Serum albumin binding agents
|
|
JP2021500856A
(ja)
|
2017-09-13 |
2021-01-14 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
Ｉｌ−６ｒ抗体およびその抗原結合フラグメントならびに医薬としての使用
|
|
CN107492601A
(zh)
*
|
2017-09-30 |
2017-12-19 |
京东方科技集团股份有限公司 |
一种显示器件及其封装方法、显示装置
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
PE20201183A1
(es)
|
2017-10-13 |
2020-11-03 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso
|
|
KR102771895B1
(ko)
|
2017-10-20 |
2025-02-21 |
가꼬우호우징 효고 이카다이가쿠 |
항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
|
|
CA3076791A1
(en)
|
2017-10-31 |
2019-05-09 |
Vib Vzw |
Novel antigen-binding chimeric proteins and methods and uses thereof
|
|
CN111386285B
(zh)
|
2017-11-15 |
2024-08-27 |
诺和诺德股份有限公司 |
增强fx活化的因子x结合物
|
|
JP7482630B2
(ja)
|
2017-11-28 |
2024-05-14 |
中外製薬株式会社 |
抗原結合ドメインおよび運搬部分を含むポリペプチド
|
|
KR20200089312A
(ko)
|
2017-11-28 |
2020-07-24 |
추가이 세이야쿠 가부시키가이샤 |
리간드 결합 활성을 조정 가능한 리간드 결합 분자
|
|
US10941213B2
(en)
|
2018-01-26 |
2021-03-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-TMPRSS2 antibodies and antigen-binding fragments
|
|
SG11202006902QA
(en)
|
2018-02-06 |
2020-08-28 |
Ablynx Nv |
Methods of treating initial episode of ttp with immunoglobulin single variable domains
|
|
WO2019155041A1
(en)
|
2018-02-12 |
2019-08-15 |
Vib Vzw |
Gβγ COMPLEX ANTIBODIES AND USES THEREOF
|
|
WO2019162521A1
(en)
|
2018-02-26 |
2019-08-29 |
Ablynx Nv |
Improved nucleotide sequences encoding peptide linkers
|
|
WO2019168897A2
(en)
|
2018-02-28 |
2019-09-06 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
|
|
JP2021514649A
(ja)
|
2018-03-01 |
2021-06-17 |
ブレイエ・ユニバージテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｔｅｉｔ Ｂｒｕｓｓｅｌ |
ヒトｐｄ−ｌ１結合免疫グロブリン
|
|
AU2019253462B2
(en)
|
2018-04-09 |
2025-04-24 |
Amgen Inc. |
Growth differentiation factor 15 fusion proteins
|
|
CN119192397A
(zh)
|
2018-05-14 |
2024-12-27 |
哈普恩治疗公司 |
用于条件性激活免疫球蛋白分子的结合部分
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
EP3636657A1
(en)
|
2018-10-08 |
2020-04-15 |
Ablynx N.V. |
Chromatography-free antibody purification method
|
|
TWI860325B
(zh)
|
2019-01-31 |
2024-11-01 |
法商賽諾菲生物技術公司 |
用於治療幼年原發性關節炎之組成物及方法
|
|
WO2020185069A1
(en)
|
2019-03-08 |
2020-09-17 |
Linxis B.V. |
Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
|
|
BR112021021077A2
(pt)
|
2019-04-24 |
2021-12-14 |
E Zilberstein Moshe |
Métodos de diagnóstico e tratamento de artrite reumatoide
|
|
CA3138028A1
(en)
|
2019-04-29 |
2020-11-05 |
Confo Therapeutics N.V. |
Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs
|
|
EP3962599A1
(en)
|
2019-04-30 |
2022-03-09 |
Vib Vzw |
Cystic fibrosis transmembrane conductance regulator stabilizing agents
|
|
WO2020223121A1
(en)
|
2019-04-30 |
2020-11-05 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
|
MX2021014007A
(es)
|
2019-05-14 |
2022-01-24 |
Harpoon Therapeutics Inc |
Proteinas de union a epcam y metodos de uso.
|
|
EP3976067A1
(en)
|
2019-05-28 |
2022-04-06 |
Vib Vzw |
Cd8+ t-cells lacking plexins and their application in cancer treatment
|
|
US20220220197A1
(en)
|
2019-05-28 |
2022-07-14 |
Vib Vzw |
Cancer Treatment by Targeting Plexins in the Immune Compartment
|
|
WO2020247461A1
(en)
|
2019-06-04 |
2020-12-10 |
Sanofi Biotechnology |
Compositions and methods for treating pain in subj ects with rheumatoid arthritis
|
|
AU2020296979A1
(en)
|
2019-06-21 |
2022-02-24 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
US12247079B2
(en)
|
2019-06-21 |
2025-03-11 |
Sorriso Pharmaceuticals, Inc. |
Polynucleotides encoding, and method of making, a polypeptide comprising a VHH which binds interleukin-receptor (IL-7R)
|
|
BR112022004534A2
(pt)
|
2019-09-20 |
2022-06-07 |
Invectys SAS |
Anticorpos de domínio único direcionados contra lilrb2
|
|
TW202128775A
(zh)
|
2019-10-16 |
2021-08-01 |
英商阿法克塔生命科學有限公司 |
PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
|
|
US20220380456A1
(en)
|
2019-10-21 |
2022-12-01 |
Vib Vzw |
Nanodisc-specific antigen-binding chimeric proteins
|
|
US20220386594A1
(en)
|
2019-11-11 |
2022-12-08 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Insect control nanobodies and uses thereof
|
|
EP4065603A1
(en)
|
2019-11-27 |
2022-10-05 |
Vib Vzw |
Positive allosteric modulators of the calcium-sensing receptor
|
|
WO2021113736A1
(en)
|
2019-12-05 |
2021-06-10 |
Massachusetts Institute Of Technology |
Single-domain antibody to chloramphenicol
|
|
MX2022006880A
(es)
|
2019-12-06 |
2022-07-11 |
Ablynx Nv |
Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23.
|
|
CN114980923A
(zh)
|
2019-12-06 |
2022-08-30 |
艾伯霖克斯公司 |
包含靶向TNFα和OX40L的免疫球蛋白单可变结构域的多肽
|
|
MX2022007035A
(es)
|
2019-12-09 |
2022-06-23 |
Ablynx Nv |
Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
|
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
|
CA3165429A1
(en)
|
2019-12-20 |
2021-06-24 |
Vib Vzw |
Nanobody exchange chromatography
|
|
WO2021140205A1
(en)
|
2020-01-10 |
2021-07-15 |
Confo Therapeutics N.V. |
Methods for generating antibodies and antibody fragments and libraries comprising same
|
|
EP4093513A4
(en)
|
2020-01-24 |
2024-05-08 |
Dana-Farber Cancer Institute, Inc. |
Uses of biomarkers for improving immunotherapy
|
|
WO2021156490A2
(en)
|
2020-02-06 |
2021-08-12 |
Vib Vzw |
Corona virus binders
|
|
JP7772702B2
(ja)
|
2020-02-10 |
2025-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｔｍｐｒｓｓ２抗体および抗原結合断片
|
|
IL295448A
(en)
|
2020-02-21 |
2022-10-01 |
Harpoon Therapeutics Inc |
flt3 binding proteins and methods of use
|
|
CN115698047A
(zh)
|
2020-02-25 |
2023-02-03 |
非营利性组织佛兰芒综合大学生物技术研究所 |
富含亮氨酸的重复激酶2变构调节剂
|
|
JP2023519967A
(ja)
|
2020-03-30 |
2023-05-15 |
アブリンクス・エヌ・フェー |
多価免疫グロブリン単一可変ドメインの製造及び精製のための方法
|
|
MX2021004130A
(es)
|
2020-04-02 |
2021-06-15 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno.
|
|
CN113527488A
(zh)
|
2020-04-22 |
2021-10-22 |
迈威(上海)生物科技股份有限公司 |
一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物
|
|
WO2021233246A1
(en)
*
|
2020-05-18 |
2021-11-25 |
Biosion Inc. |
Antibodies binding il6r and uses thereof
|
|
AU2021282179A1
(en)
|
2020-05-26 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
JP2023541934A
(ja)
|
2020-09-16 |
2023-10-04 |
リンクシス ベスローテン フェンノートシャップ |
内在化結合分子
|
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
|
CA3196737A1
(en)
|
2020-09-24 |
2022-03-31 |
Massimiliano Mazzone |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
|
MX2023003522A
(es)
|
2020-09-25 |
2023-04-19 |
Ablynx Nv |
Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
|
|
WO2022087339A1
(en)
|
2020-10-23 |
2022-04-28 |
Alexion Pharmaceuticals, Inc. |
Methods of treating patients having complement disorders using anti-c5 antibodies
|
|
WO2022117569A1
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
|
|
JP2024508207A
(ja)
|
2020-12-02 |
2024-02-26 |
ブイアイビー ブイゼットダブリュ |
がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
US11946055B2
(en)
*
|
2020-12-10 |
2024-04-02 |
The Regents Of The University Of California |
Protein engineering via error-prone orthogonal replication and yeast surface display
|
|
JP2023553694A
(ja)
|
2020-12-18 |
2023-12-25 |
アブリンクス エン．ヴェー． |
ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
|
|
TW202241948A
(zh)
|
2020-12-18 |
2022-11-01 |
比利時商艾伯霖克斯公司 |
基於TCR α/β反應性的T細胞募集多肽
|
|
CA3205422A1
(en)
|
2020-12-18 |
2022-06-23 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
|
|
GB202020502D0
(en)
|
2020-12-23 |
2021-02-03 |
Vib Vzw |
Antibody composistion for treatment of corona virus infection
|
|
CA3206125A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Murine cross-reactive human ccr8 binders
|
|
WO2022136649A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Non-blocking human ccr8 binders
|
|
WO2022136647A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Human ccr8 binders
|
|
WO2022159793A2
(en)
|
2021-01-25 |
2022-07-28 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for identifying neuroendocrine prostate cancer
|
|
CN117794566A
(zh)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
沙贝病毒结合剂
|
|
US20240101647A1
(en)
|
2021-02-05 |
2024-03-28 |
Vib Vzw |
Sarbecovirus binders
|
|
EP4291175A1
(en)
|
2021-02-11 |
2023-12-20 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancers using sting agonists
|
|
US20240130999A1
(en)
|
2021-02-17 |
2024-04-25 |
Vib Vzw |
Inhibition of SLC4A4 in the Treatment of Cancer
|
|
EP4294834A2
(en)
|
2021-02-19 |
2023-12-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Single domain antibodies that neutralize sars-cov-2
|
|
IL305318A
(en)
|
2021-02-19 |
2023-10-01 |
Vib Vzw |
Cation-independent mannose-6-phosphate receptor binders
|
|
US12454572B2
(en)
|
2021-03-02 |
2025-10-28 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating anemia in myelodysplastic syndromes
|
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
|
US20250319183A1
(en)
|
2021-04-07 |
2025-10-16 |
David Avigan |
Compositions and methods for the treatment of cancer
|
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
|
JP2024523921A
(ja)
|
2021-06-23 |
2024-07-02 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
特異的バインダーの選択手段及び方法
|
|
BR112024000744A2
(pt)
|
2021-07-14 |
2024-04-30 |
Regeneron Pharma |
Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno
|
|
CA3228014A1
(en)
|
2021-07-30 |
2023-02-16 |
Vib Vzm |
Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
|
|
US20240409638A1
(en)
|
2021-10-07 |
2024-12-12 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
|
US20250243277A1
(en)
|
2021-10-07 |
2025-07-31 |
Avacta Life Sciences Limited |
Pd-l1 binding affimers
|
|
CN114085287B
(zh)
*
|
2021-11-12 |
2022-10-25 |
中国农业科学院北京畜牧兽医研究所 |
犬细小病毒纳米抗体cpv-vhh-f5及其应用
|
|
EP4433592A1
(en)
|
2021-11-18 |
2024-09-25 |
Circularis Biotechnologies, Inc. |
Compositions and methods for production of circular nucleic acid molecules
|
|
CN118302818A
(zh)
|
2021-11-22 |
2024-07-05 |
阿布林克斯有限公司 |
获得目标多价免疫球蛋白单可变结构域的序列信息
|
|
EP4440594A2
(en)
|
2021-11-29 |
2024-10-09 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
|
CA3242445A1
(en)
|
2021-12-17 |
2023-06-22 |
Ablynx N.V. |
Polypeptides comprising immunoglobulin single variable domains targeting tcras, cd33 and cd123
|
|
CA3248241A1
(en)
|
2022-01-12 |
2023-07-20 |
Vib Vzw |
HUMAN NTCP BINDERS FOR THERAPEUTIC USE AND TARGETED LIVER ADMINISTRATION
|
|
EP4476250A1
(en)
|
2022-02-07 |
2024-12-18 |
Vib Vzw |
Engineered stabilizing aglycosylated fc-regions
|
|
EP4477665A4
(en)
|
2022-02-10 |
2025-08-20 |
Affyxell Therapeutics Co Ltd |
STEFIN A PROTEIN VARIANTS THAT SPECIFICALLY BIND TO CD40L AND THEIR USES
|
|
WO2023155902A1
(en)
|
2022-02-18 |
2023-08-24 |
Chongqing Mingdao Haoyue Biotechnology Co., Ltd. |
Intranasal formulations and anti-sars-cov-2-spike protein antibodies
|
|
US20250235534A1
(en)
|
2022-04-13 |
2025-07-24 |
Vib Vzw |
An LTBR Agonist In Combination Therapy Against Cancer
|
|
WO2023215498A2
(en)
*
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
|
WO2023222825A1
(en)
|
2022-05-18 |
2023-11-23 |
Vib Vzw |
Sarbecovirus spike s2 subunit binders
|
|
AU2023285094A1
(en)
|
2022-06-08 |
2025-01-23 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
WO2023242247A1
(en)
|
2022-06-14 |
2023-12-21 |
Ablynx Nv |
Immunoglobulin single variable domains targeting t cell receptor
|
|
JP2025523630A
(ja)
|
2022-07-04 |
2025-07-23 |
ブイアイビー ブイゼットダブリュ |
血液－脳脊髄液関門通過抗体
|
|
EP4558520A1
(en)
|
2022-07-18 |
2025-05-28 |
Ablynx N.V. |
Cx3cr1-binding compounds, uses thereof and related methods
|
|
IL318486A
(en)
|
2022-07-27 |
2025-03-01 |
Ablynx Nv |
Polypeptides bind to a specific epitope of the neonatal Fc receptor
|
|
CN116162160B
(zh)
*
|
2022-08-05 |
2025-07-29 |
南京融捷康生物科技有限公司 |
一种抗il-6的单域抗体及其用途
|
|
JP2025529896A
(ja)
|
2022-08-22 |
2025-09-09 |
アブデラ セラピューティクス インク． |
Ｄｌｌ３結合分子およびその使用
|
|
EP4594348A1
(en)
|
2022-09-27 |
2025-08-06 |
Vib Vzw |
Antivirals against human parainfluenza virus
|
|
TW202430561A
(zh)
|
2022-09-30 |
2024-08-01 |
法商賽諾菲公司 |
抗cd28抗體
|
|
EP4605077A1
(en)
|
2022-10-18 |
2025-08-27 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
|
WO2024089609A1
(en)
|
2022-10-25 |
2024-05-02 |
Ablynx N.V. |
Glycoengineered fc variant polypeptides with enhanced effector function
|
|
EP4615842A1
(en)
|
2022-11-09 |
2025-09-17 |
Merck Patent GmbH |
Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity
|
|
US12195546B2
(en)
|
2022-12-19 |
2025-01-14 |
Sanofi |
CD28/OX40 bispecific antibodies
|
|
WO2024137731A2
(en)
|
2022-12-21 |
2024-06-27 |
Genzyme Corporation |
Anti‑pd‑1×4‑1bb binding proteins
|
|
TW202440614A
(zh)
|
2022-12-23 |
2024-10-16 |
比利時商艾伯霖克斯公司 |
基於蛋白質的接合載體
|
|
IL321915A
(en)
|
2023-01-09 |
2025-09-01 |
Odyssey Therapeutics Inc |
Anti-TNFR2 antigen-binding proteins and their uses
|
|
WO2024156888A1
(en)
|
2023-01-27 |
2024-08-02 |
Vib Vzw |
Cd163-binding conjugates
|
|
WO2024156881A1
(en)
|
2023-01-27 |
2024-08-02 |
Vib Vzw |
CD8b-BINDING POLYPEPTIDES
|
|
WO2024168279A2
(en)
|
2023-02-10 |
2024-08-15 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
|
|
KR20250151445A
(ko)
|
2023-02-17 |
2025-10-21 |
아블린쓰 엔.브이. |
신생아 fc 수용체에 결합하는 폴리펩티드
|
|
WO2024175787A1
(en)
|
2023-02-24 |
2024-08-29 |
Vrije Universiteit Brussel |
Anti-inflammatory pannexin 1 channel inhibitors
|
|
TW202444757A
(zh)
|
2023-03-14 |
2024-11-16 |
美商奧迪希治療公司 |
抗cd25抗原結合蛋白及其用途
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
EP4680632A2
(en)
|
2023-03-17 |
2026-01-21 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024200987A1
(en)
|
2023-03-31 |
2024-10-03 |
Avacta Life Sciences Limited |
Tnfr2 binding polypeptides and methods of use
|
|
FR3147278A1
(fr)
|
2023-03-31 |
2024-10-04 |
Avacta Life Sciences Limited |
Polypeptides de liaison au tnfr2 et procedes d'utilisation
|
|
AU2024243709A1
(en)
|
2023-04-03 |
2025-11-06 |
Katholieke Universiteit Leuven |
Blood-brain barrier crossing antibodies
|
|
AU2024261810A1
(en)
|
2023-04-24 |
2025-11-13 |
Merck Sharp & Dohme Llc |
Trop2 binders and conjugates thereof
|
|
WO2024231447A1
(en)
|
2023-05-08 |
2024-11-14 |
Sanofi |
Glycosylation of immunoglobulin single variable domains
|
|
WO2024231348A1
(en)
|
2023-05-11 |
2024-11-14 |
Vib Vzw |
Slc4a4/nbce1 inhibitors
|
|
WO2024238790A1
(en)
|
2023-05-17 |
2024-11-21 |
Odyssey Therapeutics, Inc. |
Modified single-domain antibodies
|
|
CN121311939A
(zh)
|
2023-06-05 |
2026-01-09 |
赛诺菲 |
使用机器学习模型预测免疫球蛋白单可变结构域的热稳定性
|
|
WO2024261235A1
(en)
|
2023-06-22 |
2024-12-26 |
Ablynx Nv |
Chimeric proteins for modulating cytokine receptor activity
|
|
TW202515916A
(zh)
|
2023-06-22 |
2025-04-16 |
比利時商艾伯霖克斯公司 |
靶向pd-l1的免疫球蛋白單可變結構域
|
|
WO2024261344A1
(en)
|
2023-06-23 |
2024-12-26 |
Vib Vzw |
Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
|
|
AU2024308381A1
(en)
|
2023-06-29 |
2025-11-20 |
Odyssey Therapeutics, Inc. |
Anti-trailr2 antigen-binding proteins and uses thereof
|
|
TW202517676A
(zh)
|
2023-07-05 |
2025-05-01 |
比利時商艾伯霖克斯公司 |
用於治療ＩｇＧ相關疾病及病症之改良ＦｃＲｎ拮抗劑
|
|
US20250051434A1
(en)
|
2023-08-11 |
2025-02-13 |
Merck Sharp & Dohme Llc |
Monovalent interleukin 12 (il-12) heterodimeric fc proteins
|
|
TW202525845A
(zh)
|
2023-08-23 |
2025-07-01 |
法商賽諾菲公司 |
基於ｃｔｌａ—４之溶體降解劑及其用途
|
|
AR133725A1
(es)
|
2023-09-04 |
2025-10-29 |
Sanofi Sa |
Polipéptidos para uso en el tratamiento de tumores que expresan glipicano-3
|
|
AR133903A1
(es)
|
2023-09-22 |
2025-11-12 |
Ablynx Nv |
Agentes de unión de albúmina bi- y multivalentes
|
|
TW202530265A
(zh)
|
2023-10-13 |
2025-08-01 |
美商奧迪希治療公司 |
抗cdh17抗原結合蛋白及其用途
|
|
TW202535925A
(zh)
|
2023-10-25 |
2025-09-16 |
比利時商艾伯霖克斯公司 |
具有增強的Ｆｃ受體結合之Ｆｃ結構域變體
|
|
WO2025093683A1
(en)
|
2023-11-03 |
2025-05-08 |
Neuvasq Biotechnologies Sa |
Wnt7 signaling agonists
|
|
TW202540169A
(zh)
|
2023-11-08 |
2025-10-16 |
法商賽諾菲公司 |
基於ｃｄ２５的溶酶體降解物及其用途
|
|
WO2025109176A1
(en)
|
2023-11-22 |
2025-05-30 |
Exevir Bio Bv |
Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
|
|
WO2025114555A1
(en)
|
2023-11-30 |
2025-06-05 |
Oncospear Aps |
Anti-cd163 antibodies with improved adcc capabilities
|
|
WO2025114529A1
(en)
|
2023-12-01 |
2025-06-05 |
Ablynx Nv |
Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
|
|
WO2025125577A1
(en)
|
2023-12-14 |
2025-06-19 |
Vib Vzw |
Antibodies against influenza b virus
|
|
WO2025133252A1
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Immunoglobulin single variable domains targeting ceacam5
|
|
WO2025133253A2
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Protein-based conjugation carriers for intranuclear delivery
|
|
WO2025133166A1
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Protein-based carriers for site-specific amine conjugation
|
|
WO2025154056A1
(en)
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect cda nanobodies and uses thereof
|
|
WO2025154058A1
(en)
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect hsp70 nanobodies and uses thereof
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025181155A1
(en)
|
2024-02-26 |
2025-09-04 |
Vib Vzw |
Human beta-glucocerebrosidase binders and uses thereof
|
|
GB202403780D0
(en)
|
2024-03-15 |
2024-05-01 |
Avacta Life Sciences Ltd |
Polypeptides and methods for detecting and quantifying small molecules
|
|
WO2025196308A1
(en)
|
2024-03-22 |
2025-09-25 |
Vib Vzw |
Means and methods for displaying fc-containing proteins on cells and selection thereof
|
|
WO2025207946A1
(en)
|
2024-03-28 |
2025-10-02 |
Genzyme Corporation |
Polypeptides binding to a specific epitope of the transferrin receptor 1
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2025219231A1
(en)
|
2024-04-15 |
2025-10-23 |
Vib Vzw |
Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
|
|
WO2025229158A1
(en)
|
2024-05-01 |
2025-11-06 |
Commit Biologics Aps |
Antibodies and antibody constructs against cd38
|
|
WO2025238157A1
(en)
|
2024-05-15 |
2025-11-20 |
Katholieke Universiteit Leuven |
Multispecific binding agent suitable for use in cancer immune therapy
|
|
WO2025255558A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
|
|
WO2025255435A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Antigen-binding proteins against serum albumin and uses thereof
|
|
WO2025257408A1
(en)
|
2024-06-14 |
2025-12-18 |
Sanofi |
Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies
|
|
WO2025262150A2
(en)
|
2024-06-18 |
2025-12-26 |
Ablynx Nv |
Antibody-recruiting molecules
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|
|
WO2026006708A2
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Anti-cd25 antigen-binding proteins and uses thereof
|
|
WO2026008664A1
(en)
|
2024-07-01 |
2026-01-08 |
Vib Vzw |
Allosteric modulators of inhibitory immune receptor complexes
|